Cholangitis (primary sclerosing, PSC), with reimbursement 202

K11_CHOLANGI_STRICT

sclerosing cholangitis: A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.

Endpoint definition

FinnGen phenotype data

356077 individuals

diagram downward connector

Apply sex-specific rule None

356077

diagram downward connector
diagram bullet

Check conditions

K11_REIMB_202

19458

diagram downward connector
diagram bullet

Filter registries

Hospital Discharge: ICD-10 K83.0
Hospital discharge: ICD-9 5761
Hospital discharge: ICD-8 5750[4-5]
Cause of death: ICD-10 K83.0
Cause of death: ICD-9 5761
Cause of death: ICD-8 5750[4-5]

440

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

440

diagram downward connector

Check minimum number of events None

440

diagram downward connector

Include endpoints None

440

diagram downward connector
K11_CHOLANGI_STRICT

Extra metadata

First used in FinnGen datafreeze DF3
Parent code in ICD-10 K83
Name in latin Cholangitis

Summary Statistics

Key figures

All Female Male
Number of individuals 440 243 197
Unadjusted prevalence (%) 0.12 0.12 0.13
Mean age at first event (years) 44.09 46.68 40.89

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.07 4.20 [1.31, 13.45] 1.6e-2 28
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: K11_CHOLANGI_STRICT – Cholangitis (primary sclerosing, PSC), with reimbursement 202
GWS hits: 1

Survival analyses between endpoints

Plot

before Cholangitis (primary sclerosing, PSC), with reimbursement 202
after Cholangitis (primary sclerosing, PSC), with reimbursement 202

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Cholangitis (primary sclerosing, PSC), with reimbursement 202